Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost
Zolty, Ronald, Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction(CHAMPS-HF), 20419, Novartis Pharmaceuticals Corporation, 02/21/17-03/30/20, $132,921, $33,779, $166,700
Zolty, Ronald, PIONEER STUDY: A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696) versusenalapril on changes in NT-proBNP and safety and, 20195, Novartis Pharmaceuticals Corporation02/23/17-06/30/18$0, $422,582,$22,823, $445,405
Olivera-Martinez, Marco A, TARGET-HCC: A 5-year Longitudinal Observational Study of Patients with Hepatacellular Cancer, 20609, TARGET PharmaSolutions, 03/22/17-03/21/22, $335,329, $86,926, $422,255
Rochling, Fedja A, A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis, 20133Novartis Pharmaceuticals Corporation, 12/31/16-04/30/19, $120,345, $30,510, $150,855
Rochling, Fedja A, TARGET-NASH: A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis (NASH), 20513, TARGET PharmaSolutions, 01/26/17-01/25/22, $152,674, $39,435, $192,109
Rochling, Fedja A, TARGET-PBC: A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis,20512, TARGET PharmaSolutions,01/30/17-01/29/22, $186,615, $48,260, $234,875
Singh, Shailender, Pancreatic Cystic Reference Set20827University of Pittsburgh05/17/16-03/31/17, $8,364, $3,036, $11,400
Kalil, Andre C, (ARLG) Antibacterial Resistance Leadership Group: Achaogen Lung PK, 20336, Duke University, 06/01/16-11/30/16, $11,411, $5,763, $17,174
Sandkovsky, Uriel Sebastian,Risk Factors for Development of CMV Resistance in Solid Organ Transplantation, 20173, Merck & Co, Inc., 10/18/16-10/17/17, $20,272, $6,590, $26,862
Swindells, Susan, Title III:Categorical Grant Program to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White Part C Outpatient EIS Program, 6247, DHHS/HRSA, 01/01/16-12/31/17, $397,573, $0, $397,573
Swindells, Susan, AIDS Clinical Trials Group Network (ACTG), 16481, Brigham & Women's Hospital, 12/01/16-11/30/17, $50,400, $25,452, $75,852
Swindells, Susan, AIDS Clinical Trials Group (ACTG): Protocol Chair Support, 20097, Brigham & Women's Hospital12/01/16-11/30/17, $12,500, $6,312, $18,812
Swindells, Susan, A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI-based…, 20165, GlaxoSmithKline12/28/16-12/27/17, $231,418, $56,252, $287,670
Swindells, Susan, A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an …, 20164, GlaxoSmithKline, 12/28/16-12/27/17, $317,560, $82,306, $399,866
Swindells, Susan, Title III: Categorical Grant Program to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White Part C Outpatient EIS Program)6247DHHS/HRSA01/01/17-12/31/17, $378,574, $0, $378,574,
Zimmer, Andrea Joan, MAT Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles, 20530, Astellas Pharma Global Development, Inc., 03/22/17-03/21/21, $36,649, $8,749, $45,398
Zimmer, Andrea Joan, PMC A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species, 20529, Astellas Pharma Global Development, Inc., 03/22/17-03/21/21, $6,514, $914, $7,428
Miles, Clifford Douglas, Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression, 19933, Bristol-Meyers Squibb Pharmaceutical Research Institute, 11/04/16-12/31/18, $276,228, $71,559, $347,787
Plumb, Troy John, Prospective Multicenter, Open Label, Non-Randomized, Cross-Over Study Evaluating the Use of the Tablo? Hemodialysis System In-Center and In-Home by Subjects with End Stage Renal Disease (ESRD) who are on Stable Dialysis Regimens (TABLO), 18916, Outset Medical, Inc., 01/30/17-01/31/18, $$96,232, $24,370, $120,602
Holstein, Sarah A, Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma20623DHHS/NIH/NCI08/12/16-12/31/17, $18,916, $9,552, $28,468
Lunning, Matthew A, Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions20239, National Marrow Donor Program, 08/19/16-08/18/20, $73,392, $0, $73,392
Marr, Alissa Sue, The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, 19872, American Society of Clinical Oncology [ASCO], 10/07/16-10/06/19, $16,283, $3,714, $19,997
Vose, Julie M,A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma, 19969, Merck Sharp & Dohme Corp.01/03/17-07/31/19, $139,200, $35,542, $174,742
Grant, Kathleen M, Intensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers, 20806, Palo Alto Institute for Research and Education, Inc., 09/01/16-06/30/17, $77,138, $38,954, $116,092
Murphy, Peter James, A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System, 20461, Cincinnati Children's Hospital Medical Center, 07/01/16-12/31/16, $13,889, $1,111, $15,000
Nordgren, Tara Marie, Role of dietary microRNAs on human macrophage function, 20502, University of Nebraska – Lincoln12/01/16-05/31/17, $27,624, $0, $27,624
Nordgren, Tara Marie, Food For Health Seed Grant: Prevention of human disease by food-borne microRNAs (EPSCoR), 20451, University of Nebraska – Lincoln, 01/01/17-04/30/18, $16,501, $0, $16,501
Thompson, Austin Bassett, Uptravi (SelexiPag): The Users Drug Registry (SPHERE), 20328, Actelion Pharmaceuticals US, Inc., 11/22/16-11/21/17, $31,248, $7,344, $38,592
Thompson, Austin Bassett,An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease20198United Therapeutics Corporation01/25/17-01/24/18, $46,621, $11,341, $57,962
Thompson, Austin Bassett, A Multicenter, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension, 20197United Therapeutics Corporation01/25/17-01/24/18, $48,411, $11,807, $60,218
Michaud, Kaleb D, The risks of mortality, cardiovascular events, and diabetes associated with statin use in patients with rheumatoid arthritis, 20158, Pfizer, Inc., 12/16/16-12/15/17, $119,667, $30,333, $150,000
Thiele, Geoffrey Milton, Malondialdehyde-Acetaldehyde (MAA) Adducts and Anti-MAA Antibodies in Abatacept Treatment Response in Rheumatoid Arthritis (RA), 20146, Bristol-Myers Squibb Company, 12/19/16-12/18/17, $109,065, $32,720, $141,785